News

Do you have an
FSHD topic or story
that you’d like to share?

We share ‘Progress’ our monthly newsletter with our community at large. If you have a story, questions or topics of interest you’d like read about, please contact us, as we’d love to hear from you.

Send an email to admin@fshdglobal.org.

Whole-Body MRI in FSHD: Review and Future Directions

A review of the pioneering research that uses MRI scans and AI to enable clinical trials for FSH muscular dystrophy and other neuromuscular conditions.

May 27, 2026

A moment worth celebrating – the release of the interim report from Project Mercury

Project Mercury was established in 2023 to address critical challenges for clinical trials – ensuring safe and effective treatments reach patients quickly, equitably, and at scale.

May 25, 2026

Letter to the FSHD Community from Sarepta

26 March 2026 We welcome the announcement from Sarepta Therapeutics on early clinical data from its siRNA program targeting FSHD.

March 26, 2026

Letter to the FSHD Community from Roche

19 March 2026 Overnight, Roche has shared with the FSHD community that it will discontinue its Phase II MANOEUVRE trial

March 20, 2026

FSHD Global Partners with Leading Paediatric Institutions to Advance Research for Children

August 2025 FSHD Global Research Foundation recently visited the Murdoch Children’s Research Institute (MCRI) and The Royal Children’s Hospital to

September 26, 2025

Sydney FSHD Community Meeting: A Night of Innovation and Unity

On September 15th, the Sydney FSHD community gathered for an unforgettable evening of connection and discovery. Generously hosted by UBS,

September 22, 2025

World-first disease progression model offers new hope for muscular dystrophy patients

Patients with a common type of muscular dystrophy a world-first AI powered disease progression model with ‘life-changing’ implications, using advanced

September 13, 2025